Cost-effectiveness of bladder cancer screening

Yair Lotan; Robert S. Svatek

doi:10.1586/14737167.7.6.627

Cost-effectiveness of bladder cancer screening

Yair Lotan, Robert S. Svatek

Producción científica: Review article › revisión exhaustiva

2 Citas (Scopus)

Resumen

Bladder cancer is the fourth most common cancer in men and 25% of patients present with advanced disease resulting in a poor prognosis. Urine-based tests, including evaluation for blood in the urine or tumor markers, may allow early detection of cancer with resultant improved survival. Studies need to be performed to evaluate the feasibility and cost-effectiveness of screening high-risk populations such as smokers.

Idioma original	English (US)
Páginas (desde-hasta)	627-632
Número de páginas	6
Publicación	Expert Review of Pharmacoeconomics and Outcomes Research
Volumen	7
N.º	6
DOI	https://doi.org/10.1586/14737167.7.6.627
Estado	Published - dic 2007
Publicado de forma externa	Sí

ASJC Scopus subject areas

Pharmacology (medical)
Health Policy

Acceder al documento

10.1586/14737167.7.6.627

Otros archivos y enlaces

Citar esto

@article{cda1468708ea491a8d5111e814526188,

title = "Cost-effectiveness of bladder cancer screening",

abstract = "Bladder cancer is the fourth most common cancer in men and 25% of patients present with advanced disease resulting in a poor prognosis. Urine-based tests, including evaluation for blood in the urine or tumor markers, may allow early detection of cancer with resultant improved survival. Studies need to be performed to evaluate the feasibility and cost-effectiveness of screening high-risk populations such as smokers.",

keywords = "Bladder cancer, Cost-effectiveness, Screening",

author = "Yair Lotan and Svatek, {Robert S.}",

year = "2007",

month = dec,

doi = "10.1586/14737167.7.6.627",

language = "English (US)",

volume = "7",

pages = "627--632",

journal = "Expert Review of Pharmacoeconomics and Outcomes Research",

issn = "1473-7167",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - Cost-effectiveness of bladder cancer screening

AU - Lotan, Yair

AU - Svatek, Robert S.

PY - 2007/12

Y1 - 2007/12

N2 - Bladder cancer is the fourth most common cancer in men and 25% of patients present with advanced disease resulting in a poor prognosis. Urine-based tests, including evaluation for blood in the urine or tumor markers, may allow early detection of cancer with resultant improved survival. Studies need to be performed to evaluate the feasibility and cost-effectiveness of screening high-risk populations such as smokers.

AB - Bladder cancer is the fourth most common cancer in men and 25% of patients present with advanced disease resulting in a poor prognosis. Urine-based tests, including evaluation for blood in the urine or tumor markers, may allow early detection of cancer with resultant improved survival. Studies need to be performed to evaluate the feasibility and cost-effectiveness of screening high-risk populations such as smokers.

KW - Bladder cancer

KW - Cost-effectiveness

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=37549068534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549068534&partnerID=8YFLogxK

U2 - 10.1586/14737167.7.6.627

DO - 10.1586/14737167.7.6.627

M3 - Review article

C2 - 20528324

AN - SCOPUS:37549068534

SN - 1473-7167

VL - 7

SP - 627

EP - 632

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

IS - 6

ER -

Cost-effectiveness of bladder cancer screening

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto